What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2025-05-14 compared with 2024-11-14 · 25 added, 220 removed, 13 unchanged (95% of the section changed)

OTHER INFORMATION

following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

and Plan of Merger, dated as of September 30, 2022, by and among TradeUP Acquisition Corp., Tradeup Merger Sub Inc.

Immunopharma, Inc.

(incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC on October 3, 2022,

and Restated Certificate of Incorporation of Estrella Immunopharma, Inc.

(incorporated by reference to Exhibit 3.1 to the Company’s

Current Report on Form 8-K filed with the SEC on October 5, 2023)

and Restated Bylaws of Estrella Immunopharma, Inc.

(incorporated by reference to Exhibit 3.2 to the Company’s Current Report

on Form 8-K filed with the SEC on October 5, 2023)

Unit Certificate (incorporated by reference to Exhibit 4.1 to Amendment No.

9 to the Registration Statement on Form S-1/A filed with

the SEC on July 9, 2021, File No.

Common Stock Certificate.

(incorporated by reference to Exhibit 4.2 to Amendment No.

9 to the Registration Statement on Form S-1/A

filed with the SEC on July 9, 2021, File No.

Warrant Certificate (included as Exhibit A to Exhibit 4.4 below)

Agreement, dated July 14, 2021, between TradeUP Acquisition Corp.

and VStock Transfer, LLC, as warrant agent (incorporated by reference

to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on July 19, 2021, File No.

Note, dated July 25, 2022, issued by TradeUP Acquisition Corp.

to Running Lion Holdings Limited (incorporated by reference to Exhibit

10.1 to the Current Report on Form 8-K filed with the SEC on July 27, 2022, File No.

Note, dated July 25, 2022, issued by TradeUP Acquisition Corp.

to Tradeup INC.

(incorporated by reference to Exhibit 10.2 to the

Current Report on Form 8-K filed with the SEC on July 27, 2022, File No.

Agreement, dated June 28, 2022, by and between Eureka Therapeutics, Inc.

and Estrella Immunopharma, Inc.

incorporated by reference

to Exhibit 10.3 to the registration statement on Form S-4/A filed with the SEC on July 7, 2023 (File No.

Agreement, dated June 28, 2022, by and among Eureka Therapeutics, Inc., Eureka Therapeutics (Cayman) Ltd.

and Estrella Immunopharma,

incorporated by reference to Exhibit 10.4 to the registration statement on Form S-4/A filed with the SEC on July 7, 2023 (File

Agreement, dated June 28, 2022, by and between Eureka Therapeutics, Inc.

and Estrella Immunopharma, Inc.

incorporated by reference

to Exhibit 10.5 to the registration statement on Form S-4/A filed with the SEC on July 7, 2023 (File No.

Collaboration

Agreement, dated October 29, 2021, by and between Estrella Immunopharma, Inc.

(as successor to Eureka Therapeutics, Inc.) and Imugene

Limited incorporated by reference to Exhibit 10.6 to the registration statement on Form S-4/A filed with the SEC on July 7, 2023

to Executive Offer Letter, by and between Estrella Immunopharma, Inc.

Cheng Liu incorporated by reference to Exhibit 10.16

to the Current Report on Form 8-K filed with the SEC on October 5, 2023

to Employment Agreement, by and between Estrella Immunopharma, Inc.

and Jiandong (Peter) Xu incorporated by reference to Exhibit

10.17 to the Current Report on Form 8-K filed with the SEC on October 5, 2023

to Employment Agreement, by and between Estrella Immunopharma, Inc.

and Qian (Vicky) Yang incorporated by reference to Exhibit 10.18

to the Current Report on Form 8-K filed with the SEC on October 5, 2023

Agreement, dated September 30, 2022, by and among TradeUP Acquisition Corp., Estrella Immunopharma, Inc., TradeUP Acquisition Sponsor

LLC, Tradeup INC.

and the officers and directors of TradeUP Acquisition Corp.

(incorporated by reference to Exhibit 10.1 to the Current

Report on Form 8-K filed with the SEC on October 3, 2022, File No.

Immunopharma, Inc.

2023 Omnibus Incentive Plan incorporated by reference to Annex C to the registration statement on Form S-4/A filed

with the SEC on July 7, 2023 (File No.

Biopharma, Inc.

Option Grant Notice, including 2022 Equity Incentive Plan incorporated by reference to Exhibit 10.12 to the registration

statement on Form S-4/A filed with the SEC on July 7, 2023 (File No.

Combination Marketing Agreement, dated July 14, 2021, among TradeUP Acquisition Corp., US Tiger Securities, Inc.

EF Hutton, division

of Benchmark Investments, LLC, and R.

Lafferty & Co., Inc.

(incorporated by reference to Exhibit 1.2 to the Current Report

on Form 8-K filed with the SEC on July 19, 2021, File No.

Rights Agreement, dated July 14, 2021, among TradeUP Acquisition Corp., TradeUP Acquisition Sponsor LLC and certain security holders

named therein (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the SEC on July 19, 2021, File

1 to Services Agreement, effective October 1, 2022, by and between Eureka Therapeutics, Inc.

and Estrella Immunopharma, Inc.

incorporated by reference to Exhibit 10.15 to the registration statement on Form S-4/A filed with the SEC on July 7, 2023 (File No.

1 to License Agreement, effective October 1, 2022, by and between Eureka Therapeutics, Inc.

and Estrella Immunopharma, Inc.

by reference to Exhibit 10.16 to the registration statement on Form S-4/A filed with the SEC on July 7, 2023 (File No.

Note, dated January 19, 2023, issued by TradeUP Acquisition Corp.

to TradeUP Acquisition Sponsor LLC (incorporated by reference to

Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on January 24, 2023, File No.

Promissory Note, dated January 19, 2023, issued by TradeUP Acquisition Corp.

to Estrella Immunopharma, Inc.

(incorporated by reference

to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on January 24, 2023, File No.

Promissory Note, dated February 19, 2023, issued by TradeUP Acquisition Corp.

to Estrella Immunopharma, Inc.

(incorporated by reference

to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on February 21, 2023, File No.

Promissory Note, dated March 17, 2023, issued by TradeUP Acquisition Corp.

to Estrella Immunopharma, Inc.

(incorporated by reference

to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on March 17, 2023, File No.

Promissory Note, dated April 12, 2023, issued by TradeUP Acquisition Corp.

to Estrella Immunopharma, Inc.

(incorporated by reference

to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on April 13, 2023, File No.

Stock Purchase Agreement, dated as of April 20, 2023, by and between TradeUP Acquisition Corp.

and White Lion Capital LLC (incorporated

by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on April 24, 2023, File No.

Rights Agreement, dated as of April 20, 2023, by and between TradeUP Acquisition Corp.

and White Lion Capital LLC.

(incorporated

by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on April 24, 2023, File No.

to the Common Stock Purchase Agreement, dated as of April 26, 2023, by and between TradeUP Acquisition Corp.

and White Lion Capital

LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on April 26, 2023, File No.

Promissory Note, dated May 19, 2023, issued by TradeUP Acquisition Corp.

to Estrella Immunopharma, Inc.

(incorporated by reference

to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 19, 2023, File No.

Note, dated June 6, 2023, issued by TradeUP Acquisition Corp.

to Tradeup INC.

(incorporated by reference to Exhibit 10.1 to the Current

Report on Form 8-K filed with the SEC on June 6, 2023, File No.

2 to Services Agreement, effective March 1, 2023, by and between Eureka Therapeutics, Inc.

and Estrella Immunopharma, Inc.

by reference to Exhibit 10.27 to the registration statement on Form S-4/A filed with the SEC on July 7, 2023 (File No.

2 to License Agreement, effective March 1, 2023, by and between Eureka Therapeutics, Inc.

and Estrella Immunopharma, Inc.

by reference to Exhibit 10.28 to the registration statement on Form S-4/A filed with the SEC on July 7, 2023 (File No.

Promissory Note, dated June 16, 2023, issued by TradeUP Acquisition Corp.

to Estrella Immunopharma, Inc.

(incorporated by reference

to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on June 20, 2023, File No.

Agreement dated September 14, 2023 by and among TradeUP Acquisition Corp.

and Plentiful Limited (incorporated by reference to Exhibit

10.1 to the Current Report on Form 8-K filed with the SEC on September 20, 2023)

Agreement dated September 14, 2023 by and among TradeUP Acquisition Corp.

and Lianhe World Limited (incorporated by reference to

Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on September 20, 2023)

to the Estrella Series A Purchase Agreement by and between Estrella Biopharma, Inc.

and Lianhe World Limited (incorporated by reference

to Exhibit 10.4 to the Current Report on Form 8-K filed with the SEC on October 5, 2023)

to the Estrella Series A Purchase Agreement by and between Estrella Biopharma, Inc.

and CoFame Investments, LLC (incorporated by

reference to Exhibit 10.5 to the Current Report on Form 8-K filed with the SEC on October 5, 2023)

to the Estrella Series A Purchase Agreement by and between Estrella Biopharma, Inc.

and US Tiger Securities, Inc.

(incorporated by

reference to Exhibit 10.6 to the Current Report on Form 8-K filed with the SEC on October 5, 2023)

to the Estrella Series A Purchase Agreement by and between Estrella Biopharma, Inc.

and Smart Crest International Limited (incorporated

by reference to Exhibit 10.7 to the Current Report on Form 8-K filed with the SEC on October 5, 2023)

to the Estrella Series A Purchase Agreement by and between Estrella Biopharma, Inc.

and Yangbing Xiao (incorporated by reference

to Exhibit 10.8 to the Current Report on Form 8-K filed with the SEC on October 5, 2023)

to the Estrella Series A Purchase Agreement by and between Estrella Biopharma, Inc.

and Yuandong Wang (incorporated by reference

to Exhibit 10.9 to the Current Report on Form 8-K filed with the SEC on October 5, 2023)

Transfer Agreement by and among Cheng Liu, Jiandong (Peter) Xu and Qian (Vicky) Yang, Yuandong Wang and Estrella Biopharma, Inc.

(incorporated by reference to Exhibit 10.10 to the Current Report on Form 8-K filed with the SEC on October 5, 2023)

Transfer Agreement by and among Cheng Liu, Jiandong (Peter) Xu and Qian (Vicky) Yang, Yangbing Xiao and Estrella Biopharma, Inc.

(incorporated by reference to Exhibit 10.11 to the Current Report on Form 8-K filed with the SEC on October 5, 2023)

Transfer Agreement by and among Cheng Liu, Jiandong (Peter) Xu and Qian (Vicky) Yang, Smart Crest International Limited and Estrella

Biopharma, Inc.

(incorporated by reference to Exhibit 10.12 to the Current Report on Form 8-K filed with the SEC on October 5, 2023)

Promissory Note by and between Hongbin Zhang and Estrella Biopharma Inc.

(incorporated by reference to Exhibit 10.15 to the Current

Report on Form 8-K filed with the SEC on October 5, 2023)

agreement by and between Dr.

Cheng Liu and Estrella Immunopharma, Inc.

(incorporated by reference to Exhibit 10.19 to the Current

Report on Form 8-K filed with the SEC on October 5, 2023)

Agreement by and between Peter Xu and Estrella Immunopharma, Inc.

(incorporated by reference to Exhibit 10.20 to the Current Report

on Form 8-K filed with the SEC on October 5, 2023)

Rights Agreement, dated as of April 20, 2023, by and between TradeUP Acquisition Corp.

and White Lion Capital LLC.

(incorporated

by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on April 24, 2023, File No.

to the Common Stock Purchase Agreement, dated as of April 26, 2023, by and between TradeUP Acquisition Corp.

and White Lion Capital

LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on April 26, 2023, File No.

Placement Shares Purchase Agreement, dated July 14, 2021, among the Registrant, TradeUP Acquisition Sponsor LLC and Tradeup INC.

(incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed with the SEC on July 19, 2021)

Subscription Agreement, between the Registrant and the sponsor dated February 12, 2021 (incorporated by reference to Exhibit 10.5

to the Registration Statement on Form S-1 filed with the SEC on July 9, 2021 File No.

Subscription Agreement, between the Registrant and Tradeup INC.

dated February 12, 2021 (incorporated by reference to Exhibit 10.6

to the Registration Statement on Form S-1 filed with the SEC on July 9, 2021 File No.

of Share Purchase Agreement between the Registrant and the founders (incorporated by reference to Exhibit 10.7 to the Registration

Statement on Form S-1 filed with the SEC on June 11, 2021 File No.

Agreement, dated July 14, 2021, among the Registrant, TradeUP Acquisition Sponsor LLC, Tradeup INC.

and certain security holders

named therein (incorporated by reference to Exhibit 10.1 to the Current Report on 8-K filed with the SEC on July 19, 2021 File No.

001, dated and effective as of March 4, 2024, between Estrella Biopharma, Inc., Eureka Therapeutics, Inc.

Immunopharma, Inc.

(incorporated by reference to exhibit 10.1 to the Current Report on 8-K filed with the SEC on March 7, 2024 File

1 to Statement of Work No.

001, dated May 13, 2024 and effective as of March 4, 2024, by and among Estrella Biopharma, Inc.,

Eureka Therapeutics, Inc.

and Estrella Immunopharma, Inc.

(incorporated by reference to exhibit 10.1 to the Current Report on 8-K

filed with the SEC on May 13, 2024 File No.

During the quarter ended March 31, 2025, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule

10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

The following exhibits are filed as part of, or

incorporated by reference into, this Quarterly Report on Form 10-Q.

Description of Exhibit

Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

5 unchanged sentences

Inline XBRL Instance Document

Inline XBRL Taxonomy Extension Calculation Linkbase

Inline XBRL Taxonomy Extension Calculation Linkbase Document

Inline XBRL Taxonomy Extension Schema Document

Inline XBRL Taxonomy Extension Definition Linkbase

Inline XBRL Taxonomy Extension Definition Linkbase Document

Inline XBRL Taxonomy Extension Labels Linkbase Document

Inline XBRL Taxonomy Extension Presentation Linkbase

Cover Page Interactive Data File (formatted as Inline

XBRL and contained in Exhibit 101).

Annexes, schedules and

exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K.

The registrant agrees to furnish supplementally a copy of

any omitted attachment to the Securities and Exchange Commission on a confidential basis upon request.

Portions of this exhibit

(indicated by asterisks) have been omitted because the registrant has determined that the information is both not material and is

the type that the registrant treats as private or confidential.

These certifications are

furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18

of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities

Act of 1933, except as shall be expressly set forth by specific reference in such filing.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned, thereunto duly authorized.

IMMUNOPHARMA, INC.

Chief Executive

to the requirements of the Securities Act of 1933, as amended, this Quarterly Report has been signed below by the following persons in

the capacities and on the dates indicated.

Inline XBRL Taxonomy Extension Presentation Linkbase Document

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Annexes, schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K.

The registrant agrees to furnish supplementally a copy of any omitted attachment to the Securities and Exchange Commission on a confidential basis upon request.

Portions of this exhibit (indicated by asterisks) have been omitted because the registrant has determined that the information is both not material and is the type that the registrant treats as private or confidential.

These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ESTRELLA IMMUNOPHARMA, INC.

/s/ Cheng Liu

Principal Executive Officer and Chairman

November 14, 2024

Chief Executive Officer

Pursuant to the requirements of the Securities

Act of 1933, as amended, this Quarterly Report has been signed below by the following persons in the capacities and on the dates indicated.

Principal Executive Officer

(Principal Executive

Principal Financial Officer

November 14, 2024

(Principal Financial Officer and Principal Accounting Officer)

(Principal Financial

Officer and Principal Accounting Officer)

Chairperson and Director

Marsha Roberts

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information